TimesSquare Capital Management LLC Grows Stock Holdings in Vericel Corporation $VCEL

TimesSquare Capital Management LLC grew its stake in shares of Vericel Corporation (NASDAQ:VCEL) by 12.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 836,861 shares of the biotechnology company’s stock after buying an additional 93,472 shares during the period. TimesSquare Capital Management LLC’s holdings in Vericel were worth $26,336,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Abich Financial Wealth Management LLC bought a new stake in shares of Vericel during the 3rd quarter valued at $31,000. CWM LLC grew its holdings in Vericel by 101.3% during the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 694 shares in the last quarter. AlphaQuest LLC purchased a new position in Vericel during the 2nd quarter valued at about $60,000. Osaic Holdings Inc. increased its position in shares of Vericel by 13.7% during the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 353 shares during the period. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Vericel by 178.4% in the second quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock worth $135,000 after buying an additional 2,077 shares in the last quarter.

Vericel Price Performance

Shares of NASDAQ:VCEL opened at $35.96 on Friday. The company’s fifty day moving average price is $37.00 and its 200-day moving average price is $36.08. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of 149.84 and a beta of 1.24. Vericel Corporation has a one year low of $29.24 and a one year high of $58.77.

Analyst Ratings Changes

A number of equities analysts have recently commented on VCEL shares. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a research report on Sunday, January 25th. Weiss Ratings reissued a “hold (c-)” rating on shares of Vericel in a report on Monday, December 29th. Truist Financial reduced their price target on shares of Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Finally, Zacks Research downgraded Vericel from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Vericel has an average rating of “Moderate Buy” and an average price target of $57.50.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.